The phase I/II basket MEDIOLA trial demonstrated that olaparib in combination with an anti–PD-L1 antibody, durvalumab, for the treatment of germline BRCA 1/2 mutations that were platinum-sensitive resulted in relapse of ovarian cancer (116). Here, CD274 is linked to ovarian carcinoma.